Evergreen Therapeutics, Inc.

This study aims to see if adding a new drug called EG-007 to the standard two-drug treatment (lenvatinib plus pembrolizumab) works better for women with advanced or recurrent endometrial cancer. It will enroll about 450 patients whose cancer has progressed after initial chemother…

This early study is testing the safety of an experimental injection called EG-101 in healthy women. The goal is to gather initial safety data before testing the drug in pregnant women with severe pre-eclampsia, a serious condition that can threaten the lives of both mother and ba…

This study aims to check if adding a repurposed drug called EG-007 to the standard two-drug combination (lenvatinib and pembrolizumab) is safe for women with advanced endometrial cancer that has returned after chemotherapy. It will enroll about 28 women whose cancer is not a spec…

This study is testing if a daily oral medication called EG-301, when added to standard eye health supplements, can slow the progression of vision loss in people with a specific form of dry age-related macular degeneration (AMD). It will involve 90 participants, aged 50-75, who ha…